Detalhe da pesquisa
1.
Spatial predictors of immunotherapy response in triple-negative breast cancer.
Nature
; 621(7980): 868-876, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37674077
2.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582092
3.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
N Engl J Med
; 385(25): 2336-2347, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34914339
4.
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Breast Cancer Res Treat
; 2024 Mar 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38456970
5.
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry.
Breast Cancer Res Treat
; 201(2): 151-159, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37338729
6.
High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer.
Int J Mol Sci
; 24(4)2023 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36835014
7.
Is Axillary Assessment of Ductal Carcinoma In Situ of the Breast Necessary in All Cases?
J Surg Res
; 271: 145-153, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902737
8.
Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway.
Int J Mol Sci
; 23(21)2022 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-36362083
9.
Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis.
Int J Mol Sci
; 24(1)2022 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36613590
10.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34019819
11.
Trajectories of alcohol consumption during life and the risk of developing breast cancer.
Br J Cancer
; 125(8): 1168-1176, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34483338
12.
Sentinel lymph node BIOPSY after neoadjuvant therapy in breast cancer patients with lymph node involvement at diagnosis. Could wire localization of clipped node improve our results?
Surgeon
; 19(6): 344-350, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-33663946
13.
Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective.
Int J Mol Sci
; 22(15)2021 Jul 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34360578
14.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33138866
15.
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Breast Cancer Res
; 22(1): 124, 2020 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176887
16.
SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer.
Future Oncol
; 16(24): 1801-1813, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32633563
17.
Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer.
Int J Mol Sci
; 21(19)2020 Oct 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33050096
18.
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Breast Cancer Res Treat
; 177(1): 115-125, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31152327
19.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol
; 18(4): 545-554, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238593
20.
Physical activity and breast cancer risk by pathological subtype.
Gynecol Oncol
; 144(3): 577-585, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057355